The FDA proposes new rules allowing mutation-specific gene therapies to qualify for approval despite extremely small patient ...
The owner of this 2020 McLaren GTR sold the car with only 159 miles on the clock and nearly half a million dollars below the ...
Zevra Therapeutics, Inc. is rated a Buy, delivered robust FY25 results, with 350% revenue growth to $106.5M. Learn more about ZVRA stock here.
It is well known within the biopharma industry that clinical studies can produce any number of unexpected and possibly disappointing outcomes, including false negative results, or in statistical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results